Century Therapeutics, Inc. (IPSC): Nasdaq/NYSE listing notice — Century Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Century Therapeutics, Inc.

Nasdaq notified Century Therapeutics on Feb 26, 2025 that its stock closed below $1.00 for 31 consecutive business days.
Company has until August 25, 2025 to regain compliance by maintaining bid price of at least $1.00 for 10 consecutive days.
If not compliant, Century may transfer to Nasdaq Capital Market for an additional 180-day cure period.
Company plans to monitor bid price and consider options; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Century Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 26, 2025, Century Therapeutics, Inc. (the “Company”) received a notification letter (the “Bid Price Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 31 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Bid Price Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares o

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-019145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.